Drug Profile
Recombinant human thrombopoietin - 3SBio
Alternative Names: rHuTPO - 3SBio; Tebiao; TpiaoLatest Information Update: 06 Mar 2023
Price :
$50
*
At a glance
- Originator 3SBio
- Class Antianaemics; Colony-stimulating factors; Glycoproteins; Hepatoprotectants
- Mechanism of Action Thrombopoietin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Idiopathic thrombocytopenic purpura; Thrombocytopenia
- No development reported Aplastic anaemia
Most Recent Events
- 06 Mar 2023 3SBio completed a phase-III clinical trials in Idiopathic thrombocytopenic purpura (In children, In infants, In adolescents) in China (SC), as of June 2022
- 24 Aug 2022 3SBio plans for a NDA application in paediatric Idiopathic thrombocytopenic purpura
- 30 Jun 2022 Shenyang Sunshine Pharmaceutical completes a phase Ib/II trial for Thrombocytopenia in China, as of June 2022